Skip to content
value.today
BioLineRx Ltd. logo

BioLineRx Ltd.

BioLineRx Ltd. is listed today as BioLineRx Ltd.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of BioLineRx Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$4 MPrivate placement after listing$2 to $10 million

BioLineRx Ltd.: Private sale, Aug 2026

Investors in this round

1 investor had bought by the notice of Sep 9, 2026: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$262,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Israel

People named in the notice

  • Ella A. Sorani · Executive Officer · Chief Development Officer
  • Mali A. Zeevi · Executive Officer · Chief Financial Officer
  • Philip A. Serlin · Executive Officer · Chief Executive Officer
  • Aharon A. Schwartz · Director
  • Avraham A. Molcho · Director
  • BJ A. Bormann · Director
  • Gal A. Cohen · Director
  • Rami A. Dar · Director
  • Raphael A. Hofstein · Director
  • Sandra A. Panem · Director
  • Shaoyu A. Yan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Chardan Capital Markets LLC (CRD 000120128) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “Chardan is also entitled to 1.0% of the gross proceeds as management fee and $50,000 for accountable expenses.”
  • On the amounts: “The securities were issued in connection with an offering of (i) 480,696 American depositary shares (ADSs) and 868,225 pre-funded warrants to purchase ADSs in a registered direct offering, and (ii) unregistered warrants to purchase 2,023,382 ADSs.”
  • On the use of proceeds: “The Company intends to use the net proceeds or research and development activities and working capital and general corporate purposes.”

Signed by Mali Zeevi, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 9, 2026. Read the notice at the SEC.

optionsSEC
May 2020$4 MPrivate placement after listing$2 to $10 million

BioLineRx Ltd.: Private sale, May 2020

Investors in this round

5 investors had bought by the notice of Jun 10, 2020: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$307,510
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Israel

People named in the notice

  • Abi A. Vainstein-Haras · Executive Officer
  • Ella A. Sorani · Executive Officer
  • Mali A. Zeevi · Executive Officer
  • Philip A. Serlin · Executive Officer
  • Aharon Schwartz · Director
  • Avraham Jean Molcho · Director
  • Barbara Jean Bormann · Director
  • Michael J. Anghel · Director
  • Nurit J. Benjamini · Director
  • Raphael Jean Hofstein · Director
  • Sandra Jean Panem · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in IL, NJ, NY

Remarks in the notice

  • On fees: “H.C. Wainwright is also entitled to 1.0% of the gross proceeds as management fee, a $25,000 non-accountable expense reimbursement, a $35,000 accountable expense allowance and warrants to purchase 125,514 ADSs exercisable at $2.1875 per ADS for 2.5 years.”
  • On the amounts: “The warrants and shares underlying the warrants, the subject matter of this Form D were issued in connection with an offering of (i) 2,510,286 ADSs issued in a registered direct offering, and (ii) unregistered warrants to purchase 2,510,286 ADSs.”
  • On the use of proceeds: “Issuer expects to use proceeds from the offering for general corporate purposes, which may include but are not limited to working capital, funding clinical trials and payment of salaries and related expenses to the named executive officers.”

Signed by Mali Zeevi, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 10, 2020. Read the notice at the SEC.

optionsSEC
May 2020$9 MPrivate placement after listing$2 to $10 million

BioLineRx Ltd.: Private sale, May 2020

Investors in this round

6 investors had bought by the notice of Jun 10, 2020: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$630,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Israel

People named in the notice

  • Abi A. Vainstein-Haras · Executive Officer
  • Ella A. Sorani · Executive Officer
  • Mali A. Zeevi · Executive Officer
  • Philip A. Serlin · Executive Officer
  • Aharon Schwartz · Director
  • Avraham Jean Molcho · Director
  • Barbara Jean Bormann · Director
  • Michael J. Anghel · Director
  • Nurit J. Benjamini · Director
  • Raphael Jean Hofstein · Director
  • Sandra Jean Panem · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in IL, NJ, NY

Remarks in the notice

  • On fees: “H.C. Wainwright is also entitled to 1.0% of the gross proceeds as management fee, a $25,000 non-accountable expense reimbursement, a $35,000 accountable expense allowance and warrants to purchase 257,143 ADSs exercisable at $2.1875 per ADS for 2.5 years.”
  • On the amounts: “The warrants and shares underlying the warrants, the subject matter of this Form D were issued in connection with an offering of (i) 5,142,859 ADSs issued in a registered direct offering, and (ii) unregistered warrants to purchase 5,142,859 ADSs.”
  • On the use of proceeds: “Issuer expects to use proceeds from the offering for general corporate purposes, which may include but are not limited to working capital, funding clinical trials and payment of salaries and related expenses to the named executive officers.”

Signed by Mali Zeevi, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 10, 2020. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • BioLineRx Ltd. chose not to state its revenue in its newest notice of a funding round (Sep 2026).

    SEC Form D · Sep 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2026

That is all the official record says: BioLineRx Ltd. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of BioLineRx Ltd. are on record.

Investors#

No investor of BioLineRx Ltd. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding BioLineRx Ltd. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by BioLineRx Ltd.
NameRoleNamed in
Ella A. SoraniChief Development OfficerSep 2026
Mali A. ZeeviChief Financial OfficerSep 2026
Philip A. SerlinChief Executive OfficerSep 2026
Abi A. Vainstein-HarasExecutive officerJun 2020
Aharon A. SchwartzDirectorSep 2026
Avraham A. MolchoDirectorSep 2026
BJ A. BormannDirectorSep 2026
Gal A. CohenDirectorSep 2026
Rami A. DarDirectorSep 2026
Raphael A. HofsteinDirectorSep 2026
Sandra A. PanemDirectorSep 2026
Shaoyu A. YanDirectorSep 2026
Aharon SchwartzDirectorJun 2020
Avraham Jean MolchoDirectorJun 2020
Barbara Jean BormannDirectorJun 2020
Michael J. AnghelDirectorJun 2020
Nurit J. BenjaminiDirectorJun 2020
Raphael Jean HofsteinDirectorJun 2020
Sandra Jean PanemDirectorJun 2020

Went public since 2017. Its SEC number is that of a company listed on a stock exchange.